Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates

分组1 - Exelixis reported quarterly earnings of $0.78 per share, exceeding the Zacks Consensus Estimate of $0.68 per share, and showing an increase from $0.47 per share a year ago, resulting in an earnings surprise of +14.71% [1] - The company achieved revenues of $597.76 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.49%, and up from $539.54 million year-over-year [2] - Exelixis has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has gained approximately 14.3% since the beginning of the year, while the S&P 500 has increased by 16.5% [3] - The current consensus EPS estimate for the upcoming quarter is $0.64 on revenues of $609.17 million, and for the current fiscal year, it is $2.69 on revenues of $2.32 billion [7] - The Medical - Biomedical and Genetics industry, to which Exelixis belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]